Literature DB >> 17049627

Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs.

A Scagliarini1, C J McInnes, L Gallina, F Dal Pozzo, L Scagliarini, R Snoeck, S Prosperi, J Sales, J A Gilray, P F Nettleton.   

Abstract

(S)-1-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine [corrected] (HPMPC, cidofovir, CDV, Vistide) is an acyclic nucleoside analogue with a potent and selective activity against a broad spectrum of DNA viruses including the poxviruses. In this study we present the results of different treatment regimens in lambs experimentally infected with orf virus with different cidofovir formulations prepared in Beeler basis and Unguentum M. Our results show that choice of excipient, concentration of codofovir [corrected] and treatment regimen were all important to the clinical outcome of the therapy. Whilst one particular regimen appeared to exacerbate the lesion, treatment with 1% (w/v) cidofovir cream, prepared in Beeler basis, for 4 consecutive days did result in milder lesions that resolved in milder lesions that resolved [corrected] more quickly than untreated lesions. Furthermore the scabs of the treated animals contained significantly lower amounts of viable virus meaning there should be less contamination of the environment with virus than would normally occur.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17049627      PMCID: PMC1930164          DOI: 10.1016/j.antiviral.2006.09.008

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  30 in total

1.  Topical cidofovir for molluscum contagiosum in children.

Authors:  E J Zabawski; C J Cockerell
Journal:  Pediatr Dermatol       Date:  1999 Sep-Oct       Impact factor: 1.588

2.  Treatment of a bowenoid papulosis of the penis with local applications of cidofovir in a patient with acquired immunodeficiency syndrome.

Authors:  R Snoeck; Y Van Laethem; E De Clercq; J De Maubeuge; N Clumeck
Journal:  Arch Intern Med       Date:  2001-10-22

Review 3.  Role of cidofovir in the treatment of DNA virus infections, other than CMV infections, in immunocompromised patients.

Authors:  Robert Snoeck; Eric De Clercq
Journal:  Curr Opin Investig Drugs       Date:  2002-11

4.  A case of human orf in an immunocompromised patient treated successfully with cidofovir cream.

Authors:  K Geerinck; G Lukito; R Snoeck; R De Vos; E De Clercq; Y Vanrenterghem; H Degreef; B Maes
Journal:  J Med Virol       Date:  2001-08       Impact factor: 2.327

5.  Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures.

Authors:  R Snoeck; A Holý; C Dewolf-Peeters; J Van Den Oord; E De Clercq; G Andrei
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Atypical parapoxvirus infection in sheep.

Authors:  Geoffrey W Smith; Gail Scherba; Peter D Constable; Vincent Hsiao; Melissa J Behr; Dawn E Morin
Journal:  J Vet Intern Med       Date:  2002 May-Jun       Impact factor: 3.333

7.  Parapoxviruses are strongly inhibited in vitro by cidofovir.

Authors:  P F Nettleton; J A Gilray; H W Reid; A A Mercer
Journal:  Antiviral Res       Date:  2000-12       Impact factor: 5.970

8.  Characterization of a North American orf virus isolated from a goat with persistent, proliferative dermatitis.

Authors:  J Guo; Z Zhang; J F Edwards; R W Ermel; C Taylor; A de la Concha-Bermejillo
Journal:  Virus Res       Date:  2003-06       Impact factor: 3.303

9.  Genomic comparison of an avirulent strain of Orf virus with that of a virulent wild type isolate reveals that the Orf virus G2L gene is non-essential for replication.

Authors:  C J McInnes; A R Wood; P E Nettleton; J A Gilray
Journal:  Virus Genes       Date:  2001-03       Impact factor: 2.198

Review 10.  Cidofovir in the treatment of poxvirus infections.

Authors:  Erik De Clercq
Journal:  Antiviral Res       Date:  2002-07       Impact factor: 10.103

View more
  5 in total

1.  Assessing the efficacy of cidofovir against herpesvirus-induced genital lesions in goats using different therapeutic regimens.

Authors:  M Tempesta; G Crescenzo; M Camero; A L Bellacicco; E Tarsitano; N Decaro; J Neyts; V Martella; C Buonavoglia
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

2.  Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections.

Authors:  Fabio Sonvico; Gaia Colombo; Laura Gallina; Fabrizio Bortolotti; Alessandra Rossi; Colin J McInnes; Gina Massimo; Paolo Colombo; Alessandra Scagliarini
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

3.  Cidofovir Activity against Poxvirus Infections.

Authors:  Graciela Andrei; Robert Snoeck
Journal:  Viruses       Date:  2010-12-22       Impact factor: 5.048

Review 4.  Zoonotic Poxviruses Associated with Companion Animals.

Authors:  Danielle M Tack; Mary G Reynolds
Journal:  Animals (Basel)       Date:  2011-11-17       Impact factor: 2.752

5.  Structural basis of GM-CSF and IL-2 sequestration by the viral decoy receptor GIF.

Authors:  Jan Felix; Eaazhisai Kandiah; Steven De Munck; Yehudi Bloch; Gydo C P van Zundert; Kris Pauwels; Ann Dansercoer; Katka Novanska; Randy J Read; Alexandre M J J Bonvin; Bjorn Vergauwen; Kenneth Verstraete; Irina Gutsche; Savvas N Savvides
Journal:  Nat Commun       Date:  2016-11-07       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.